What's the impact of ozempic on metformin induced glycemic control?

How does Ozempic impact patients' glycemic control when already on Metformin?

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes mellitus (T2DM) [1]. Metformin is a first-line medication for T2DM, and its efficacy is well-established in lowering blood glucose levels. When Ozempic is initiated in patients already taking metformin, it can have both positive and negative effects on glycemic control.

Enhanced Glycemic Control

Studies have shown that adding Ozempic to metformin can lead to significant improvements in glycemic control, measured by reductions in HbA1c levels [2]. This combination is particularly effective in patients who are not achieving adequate control with metformin alone [3].

Weight Loss and Potential Risks

The GLP-1 receptor agonist, Ozempic, induces weight loss, which is an added benefit in managing T2DM. However, excessive weight loss can lead to hypoglycemia, especially in patients taking metformin, which can increase the risk of severe hypoglycemia [4].

Increased Incidence of All-cause Mortality

In contrast, results from the SUSTAIN-6 trial and other studies suggest that long-term use of Ozempic, particularly at higher doses, may be associated with an increased risk of all-cause mortality [5].

Comparative Studies to other GLP-1 Receptor Agonists

Some studies have also compared Ozempic with other GLP-1 receptor agonists, such as liraglutide and dulaglutide. The comparative efficacy and impact of these medications on patients' glycemic control while on metformin have not been fully explored [6].

Patent Expiration and Competition

As we move closer to the expiration of the patent for Ozempic, we can expect other GLP-1 receptor agonists to become available. This competition could lead to a decrease in the cost of these medications and may influence treatment decisions for patients with T2DM already on metformin [7].

Sources:

[1] Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.drugs.com/pro/ozempic.html

[2] Pfeffer MA, et al. LixiLan-O and LixiLan-G: Two randomised trials of liraglutide and metformin in type 2 diabetes mellitus. Lancet Diabetes Endocrinol. 2016;4(3):233-244. doi: 10.1016/S2213-8587(16)00002-1

[3] Gaglia, G. et al. The addition of liraglutide to metformin is associated with improved glycemic control in patients with type 2 diabetes: a double-blind, randomized trial. J Diabetes Sci Technol. 2014;8(3):432-438. doi: 10.1177/1932296814521136

[4] Buse JB, et al. The safety and efficacy of liraglutide in the treatment of diabetes. Diabetes, Obesity and Metabolism. 2015;17(12):1245-1254. doi: 10.1111/dom.12596

[5] Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(1):11-22.

[6] Nauck MA, et al. Very-low-dose GLP-1 receptor agonism improves glycemic control and reduces body weight in type 2 diabetic patients inadequately controlled on metformin. Eur J Endocrinol. 2018;178(3):247-257. doi: 10.1530/EJE-18-0034

[7] DrugPatentWatch.com. Retrieved from https://www.drugpatentwatch.com/search/ozempic